leo 39652
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2013 (NCT01850849)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Phosphodiesterase 4AINHIBITOR
PDE4A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- leo 39652
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02219633 | Phase 1 | Jul 1, 2014 | Leo Pharma, Proinnovera GmbH |
| NCT01850849 | Phase 1 | May 1, 2013 | Covance, Leo Pharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 2 | 2 | 1 | 2013 |
| Covance | For profit | 1 | 0 | 1 | 2013 |
| Proinnovera GmbH | For profit | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1